The effectiveness of Problem Management Plus at 1-year follow-up for Syrian refugees in a high-income setting.


Journal

Epidemiology and psychiatric sciences
ISSN: 2045-7979
Titre abrégé: Epidemiol Psychiatr Sci
Pays: England
ID NLM: 101561091

Informations de publication

Date de publication:
25 Oct 2024
Historique:
medline: 25 10 2024
pubmed: 25 10 2024
entrez: 25 10 2024
Statut: epublish

Résumé

Problem Management Plus (PM+) has been effective in reducing mental health problems among refugees at three-month follow-up, but there is a lack of research on its long-term effectiveness. This study examined the effectiveness of PM+ in reducing symptoms of common mental disorders at 12-month follow-up among Syrian refugees in the Netherlands. This single-blind, parallel, controlled trial randomised 206 adult Syrians who screened positive for psychological distress and impaired functioning to either PM+ in addition to care as usual (PM+/CAU) or CAU alone. Assessments were at baseline, 1 week and 3 months after the intervention and 12 months after baseline. Outcomes were psychological distress (Hopkins Symptom Checklist [HSCL-25]), depression (HSCL-25 subscale), anxiety (HSCL-25 subscale), posttraumatic stress disorder symptoms (PCL-5), functional impairment (WHODAS 2.0) and self-identified problems (PSYCHLOPS). In March 2019-December 2022, 103 participants were assigned to PM+/CAU and 103 to CAU of which 169 (82.0%) were retained at 12 months. Intention-to-treat analyses showed greater reductions in psychological distress at 12 months for PM+/CAU compared to CAU (adjusted mean difference -0.17, 95% CI -0.310 to -0.027; PM+ is effective in reducing psychological distress and symptoms of anxiety over a period up to 1 year. Additional support such as booster sessions or additional (trauma-focused) modules may be required to prolong and consolidate benefits gained through PM+ on other mental health and psychosocial outcomes.

Identifiants

pubmed: 39449610
doi: 10.1017/S2045796024000519
pii: S2045796024000519
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

e50

Auteurs

Anne M de Graaff (AM)

Department of Clinical, Neuro- and Developmental Psychology, WHO Collaborating Center for Research and Dissemination of Psychological Interventions, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Pim Cuijpers (P)

Department of Clinical, Neuro- and Developmental Psychology, WHO Collaborating Center for Research and Dissemination of Psychological Interventions, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Babeș-Bolyai University, International Institute for Psychotherapy, Cluj-Napoca, Romania.

Mariam Elsawy (M)

Department of Clinical, Neuro- and Developmental Psychology, WHO Collaborating Center for Research and Dissemination of Psychological Interventions, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Sam Hunaidy (S)

Department of Clinical, Neuro- and Developmental Psychology, WHO Collaborating Center for Research and Dissemination of Psychological Interventions, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Barbara Kieft (B)

ARQ National Psychotrauma Centre, ARQ Centrum '45, Diemen, The Netherlands.

Noer Gorgis (N)

i-Psy, Parnassia Groep, Almere, The Netherlands.

Jos W R Twisk (JWR)

Department of Epidemiology and Data Science, VU University Medical Centre Amsterdam, Amsterdam, The Netherlands.

Yenovk Zakarian (Y)

Department of Clinical, Neuro- and Developmental Psychology, WHO Collaborating Center for Research and Dissemination of Psychological Interventions, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Theo K Bouman (TK)

Clinical Psychology and Experimental Psychopathology, University of Groningen, Groningen, The Netherlands.

Miriam J J Lommen (MJJ)

Clinical Psychology and Experimental Psychopathology, University of Groningen, Groningen, The Netherlands.

Ceren Acarturk (C)

Department of Psychology, Koc University, Istanbul, Turkiye.

Richard Bryant (R)

School of Psychology, University of New South Wales, Sydney, Australia.

David McDaid (D)

Care Policy and Evaluation Centre, Department of Health Policy, London School of Economics and Political Science, London, UK.

Naser Morina (N)

Department of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

A-La Park (AL)

Care Policy and Evaluation Centre, Department of Health Policy, London School of Economics and Political Science, London, UK.

Peter Ventevogel (P)

Public Health Section, United Nations High Commissioner for Refugees, Geneva, Switzerland.

Marit Sijbrandij (M)

Department of Clinical, Neuro- and Developmental Psychology, WHO Collaborating Center for Research and Dissemination of Psychological Interventions, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH